Connect Biopharma is trading 8.71% higher at $1.06, with no October 2 company announcement or verified catalyst identified.
- The latest company press release was September 30, reporting positive preliminary Phase 2 COPD data.
- Broader markets were also higher: the Nasdaq was up 1.41%, the S&P 500 up 0.86%, and the Dow up 0.58%. This strength may be contributing, but the available evidence does not establish a specific cause for the stock’s larger gain.